Navigation Links
A protein sequence associated with Huntington’s disease may become life-saving vaccine component

On June 10, 2008 the scientific journal "Vaccine" published a paper by the Massachusetts based biotech company Cure Lab, Inc., demonstrating that a protein sequence important in neurodegenerative Huntington's disease can be safely used as a new generation of vaccine adjuvants.

The major component of every vaccine is an antigen that elicits specific immunity to a particular virus, bacteria or even cancer cells. Search for better antigens is one of the most pressing medical and public health necessities, and the biotech industry invests heavily in this research. However, antigens are able to generate a limited immune response if administered alone. In order to be protective or therapeutic, vaccine compositions have to be supplemented with adjuvants, strong facilitators of the immune response. In the search for efficient adjuvants that are also non-toxic, scientists at Cure Lab, Inc. discovered a novel paradigm that capitalizes on insights from recent breakthroughs in understanding the fatal neurodegenerative disorder, Huntington's.

Huntington's disease results from mutations in the protein huntingtin, which contains a sequence of polyglutamine residues (polyQ). In healthy individuals, huntingtin contains less than 35 glutamines in the polyQ segment. However, in neurons of Huntington's patients, the number of glutamine residues in the sequence expands to more than 36. This induces protein self-aggregation, or formation of big protein "chunks", and eventually causes neuronal dysfunction. Recent research findings indicate that attachment of a prolonged polyQ segment to almost any protein promotes its aggregation.

"There were two ideas - said Alex Shneider, Cure Lab's founder and CEO- which stimulated us to test if attachment of a long polyQ "tail" to an antigen can enhance immune response to vaccination". First, he noticed that small aggregates formed by an antigen fused to a polyQ tail resembled the droplets that conventional adjuvants formed with antigenic peptides exposed on their surface. Dr. Shneider hypothesized that these polyQ containing aggregates were easily taken up by antigen-presenting cells, as is the case with adjuvant droplets, triggering the immune response.

Another hypothesis was proposed by Michael Sherman, professor at Boston University Medical School and scientific consultant at Cure Lab. "We knew- said Michael Sherman- that polyQ aggregates are destroyed in cells by a special degradation system, called autophagy. Interestingly, autophagy plays a key role in the processing of certain antigens, which is critical for the immune response. So, attachment of a polyQ tail should specifically target the antigen to autophagy, which in turn should facilitate the response. Thus, polyQ would serve as a molecular adjuvant".

There are two branches to the immune system. One is responsible for developing antibodies against bacteria, viruses and toxins freely circulating in the organism. Another is aimed at eliminating virus-infected or cancer cells. Cure Lab's paper demonstrates that the new polyQ-based adjuvant efficiently enhances both branches of the immune response to a poor model antigen. Importantly, the adjuvant caused no apparent toxicity in mice.

Many questions remain to be answered. The adjuvant properties of the polyQ tail will have to be tested for each individual antigen of medical and veterinary importance. However, this work may launch a new era in vaccine development, the era of molecular adjuvants.


Contact: Alex Shneider
Cure Lab, Inc.

Related biology news :

1. Fruit fly helps identify protein critical to eggshell formation that may be pesticide target
2. Protein fibrils as alternative plastics?
3. Montana State University researchers map iron transport protein
4. Plant biologists discover unexpected proteins affecting small RNAs
5. New clues to how proteins dissolve and crystallize
6. Ancient protein offers clues to killer condition
7. New discovery on role of vital protein that fights meningitis
8. Researchers report the cloning of a key group of human genes, the protein kinases
9. Genetic sequencing of protein from T. rex bone confirms dinosaurs link to birds
10. Proteins that stop a major signaling pathway can also generate new proteins
11. Researchers reveal structure of protein that repairs damage to cancer cells
Post Your Comments:
(Date:3/29/2017)... , March 29, 2017  higi, the health ... in North America , today announced ... and the acquisition of EveryMove. The new investment and ... set of tools to transform population health activities through ... lifestyle data. higi collects and secures data ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed ... received the prestigious international IAIR Award for the most innovative high security ... ... Maldives Immigration Controller General, ... picture on the right) have received the IAIR award for the "Most ...
(Date:3/23/2017)... Research and Markets has announced the addition of the ... to 2025" report to their offering. ... The Global Vehicle Anti-Theft System Market ... the next decade to reach approximately $14.21 billion by 2025. ... for all the given segments on global as well as regional ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... Philadelphia, PA (PRWEB) , ... October 10, 2017 ... ... University City Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. ... accept the award for Excellence in Volunteer Experience from US2020. , US2020’s mission ...
(Date:10/10/2017)... ... 10, 2017 , ... The Pittcon Program Committee is pleased ... scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each ... leading conference and exposition for laboratory science, which will be held February 26-March ...
(Date:10/9/2017)... , ... October 09, 2017 ... ... on October 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® ... gold standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) using surface ...
(Date:10/6/2017)... ... October 06, 2017 , ... ... lunch discussion and webinar on INSIGhT, the first-ever adaptive clinical trial for glioblastoma ... Cancer Institute. The event is free and open to the public, but registration ...
Breaking Biology Technology: